Biomarker-based Alzheimer's Disease Cohort Study (BASIC)
NCT ID: NCT07109999
Last Updated: 2025-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2835 participants
OBSERVATIONAL
2019-01-01
2050-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort
NCT04924361
China Cognition and Aging Study
NCT03653156
Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study
NCT07284264
Protein and microRNA Markers for Early Detection of Alzheimer's Disease
NCT03388242
Cohort Study on Cognitive Decline in Elderly
NCT07093892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients diagnosed with Alzheimer's disease with AD biomarker positivity.
This cohort recruits patients diagnosed with Alzheimer's disease based on clinical symptoms, neuroimaging features and AD biomarkers. Biomarker positivity is necessary for inclusion.
None-placebo
This study is an observational study, and no interventions will be implemented.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
None-placebo
This study is an observational study, and no interventions will be implemented.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* (2) Visiting Xuanwu Hospital, Capital Medical University;
* (3) Meeting the core clinical diagnostic criteria for Alzheimer's disease (AD) - related mild cognitive impairment or probable AD according to the NIA-AA (2011);
* (4) Amyloid positivity confirmed by amyloid PET or cerebrospinal fluid biomarker tests;
* (5) Providing informed consent.
Exclusion Criteria
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xuanwu Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024347
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.